id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-353904-dieaqxmi	Davies, M.	Remdesivir in treatment of COVID-19: A systematic benefit-risk assessment	2020-05-12		.txt	text/plain	4057	229	49	A systematic benefit-risk assessment was designed and conducted to strengthen the ongoing understanding of the benefit-risk balance for remdesivir in COVID-19 treatment by using a structured method which uses all available data. Conclusions: Preliminary clinical trial results suggest a favourable benefit-risk profile for remdesivir compared to placebo, however there is limited safety data available at the current time. The benefits included in the value tree include key endpoints included in clinical trial protocols for studies assessing the efficacy of remdesivir in severe COVID-19 disease. Primary endpoint data available from the Adaptive COVID 19 trial [26] have also suggested a shorter time to recovery in patients treated with remdesivir, with non-significant reduced mortality risk. Preliminary clinical trial results suggest a favourable benefit-risk profile for remdesivir compared to placebo, however there is limited safety data available at the current time.	./cache/cord-353904-dieaqxmi.txt	./txt/cord-353904-dieaqxmi.txt